Chongqing Medical Center for Women and Children
11
2
4
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
18%
2 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET
Role: collaborator
NHFOV as Primary Support in Very Preterm Infants With RDS
Role: collaborator
Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS
Role: collaborator
Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study
Role: collaborator
Milk Temperature Control and Necrotizing Enterocolitis Risk in Extremely Preterm Infants
Role: collaborator
Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron
Role: collaborator
Reducing Postpartum Hemorrhage After Vaginal Delivery
Role: collaborator
Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
Role: collaborator
A Multi-center Registry Study: The Follow-up the Complications for Trans-vaginal Mesh Surgery
Role: collaborator
Epidemiological Study of Iron Deficiency and Iron Deficiency Anemia in Chinese Pregnant Women
Role: collaborator
To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation
Role: collaborator
All 11 trials loaded